Allarity Therapeutics Inc is a clinical-stage, precision medicine company. Allarity Therapeutics Inc is a clinical-stage, precision medicine company.
Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancerAllarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate stenoparib’s...
Cash balance at $18.5 millionStrengthened leadership team with new members driving stenoparib developmentNASDAQ compliance regained Boston (November 14, 2024)—Allarity Therapeutics, Inc...
European Patent Office to grant a patent for DRP® companion diagnostic for Allarity’s stenoparib cancer therapy Patent applications for the Stenoparib DRP® are also pending in the US, Japan...
Boston (October 10, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.08 | -7.27272727273 | 1.1 | 1.72 | 0.9405 | 7273139 | 1.06676291 | CS |
4 | -0.01 | -0.970873786408 | 1.03 | 1.72 | 0.9 | 2595621 | 1.07448695 | CS |
12 | -0.64 | -38.5542168675 | 1.66 | 2.255 | 0.9 | 1103352 | 1.17526003 | CS |
26 | -5.22 | -83.6538461538 | 6.24 | 7.452 | 0.9 | 2679011 | 4.40036454 | CS |
52 | -304.98 | -99.6666666667 | 306 | 327.18 | 0.9 | 2845209 | 20.19798572 | CS |
156 | 203041.096543 | -100.000502364 | -203040.076543 | 92640 | -184312.525984 | 1902970 | 1460.6450411 | CS |
260 | 250334.809414 | -100.000407456 | -250333.789414 | 92640 | -167332.373652 | 1871649 | 1350.88926397 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales